Survivors Stand up to Big Pharma

2 drug-resistant tuberculosis survivors who lost their hearing because of treatment are teaming up with Médecins Sans Frontières to challenge a patent extension on a safer drug in India.
 
The extension of Johnson & Johnson's monopoly on the WHO-recommended bedaquilin would block generic versions for 4 years longer than planned. 

MSF calls the strategy “patent evergreening.”

“If this patent application is rejected, generic versions of this drug could be available sooner at reduced prices, saving hundreds of thousands of lives and reducing immense suffering around the world, says Anja Reuter, an MSF DR-TB doctor in South Africa.

Médecins Sans Frontières (news release)

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top